Oramed Pharmaceuticals (XTAE:ORMP) Cash And Cash Equivalents : ₪262.22 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals Cash And Cash Equivalents?

Oramed Pharmaceuticals's quarterly cash and cash equivalents increased from Sep. 2024 (₪148.16 Mil) to Dec. 2024 (₪191.50 Mil) and increased from Dec. 2024 (₪191.50 Mil) to Mar. 2025 (₪262.22 Mil).

Oramed Pharmaceuticals's annual cash and cash equivalents declined from Dec. 2022 (₪142.39 Mil) to Dec. 2023 (₪31.87 Mil) but then increased from Dec. 2023 (₪31.87 Mil) to Dec. 2024 (₪191.50 Mil).

Oramed Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for Oramed Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Cash And Cash Equivalents Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

67.90

271.83

142.39

31.87

191.50

Oramed Pharmaceuticals Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															65.37	298.25	148.16	191.50	262.22

Oramed Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Oramed Pharmaceuticals (XTAE:ORMP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Oramed Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

ORMP:USA OJU1:Germany OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.